Sub menu

 

 

COVID-19 vaccine: AstraZeneca Vaxzevria

The TGA has granted provisional approval to AstraZeneca Pty Ltd for its COVID-19 vaccine.

Published

Voluntary cancellation of AstraZeneca COVID-19 vaccine: Vaxzevria

On 23 April 2024 AstraZeneca Pty Ltd voluntarily cancelled VAXZEVRIA (previously COVID-19 Vaccine AstraZeneca) from the Australian Register of Therapeutic Goods (ARTG). 

The viral vector vaccine was provisionally approved for vaccination of individuals aged 18 years and older by the TGA on 15 February 2021. This was followed by a subsequent provisional approval for use as a booster dose in the same age group on 8 February 2022.  

Cancellation of this vaccine from the ARTG was a business decision of the company, due to no current or anticipated future demand of the vaccine, and follows similar business decisions made overseas.

Related content